Orally Administered Docetaxel Nanoparticles for Cancer Prevention and Therapy via Targeted Intestinal Uptake
발표자
이혜원 (가톨릭대학교)
연구책임자
김경섭 (가톨릭대학교 성심교정)
공동저자
이혜원 (가톨릭대학교), 김경섭 (가톨릭대학교 성심교정)
초록
내용
Conventional chemotherapy administered at the maximally tolerated dose (MTD) is limited by systemic toxicity, immune suppression, and tumor recurrence and angiogenesis. To address these issues, we applied oral metronomic chemotherapy using docetaxel-loaded solid lipid nanoparticles coated with a chondroitin sulfate–glycocholic acid conjugate (~120 nm). Glycocholic acid facilitated uptake in the distal ileum via the apical sodium–bile acid transporter and lymphatic transport, resulting in improved bioavailability (34–37%) and sustained exposure up to 24 hours. Repeated oral dosing significantly suppressed tumor growth and prevented new tumor formation. Unlike conventional MTD chemotherapy, oral nanoparticles showed no detectable organ or liver toxicity and enhanced antitumor immunity by increasing effector immune cells while reducing immunosuppressive populations. Overall, these findings highlight oral nanoparticles as a safe, low-toxicity effective antitumor strategy.